NCT06549790View on ClinicalTrials.gov

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

September 15, 2029

Study Completion Date

May 15, 2030

Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
DRUG

NMS-03597812

Route of Administration: Oral

Trial Locations (7)

19713

RECRUITING

Medical Oncology Hematology Consultants, Newark

30342

RECRUITING

Blood and Marrow Transplant Group of Georgia, Atlanta

44718

RECRUITING

Gabrail Cancer Research Center, Canton

55905

RECRUITING

Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

80012

RECRUITING

Rocky Mountain Cancer Centers, Aurora

91010

RECRUITING

City of Hope - Duarte, Duarte

Sponsors
All Listed Sponsors
lead

Nerviano Medical Sciences

INDUSTRY

NCT06549790 - Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter